Faron Pharmaceuticals Ltd has announced an Extraordinary General Meeting to be held on September 22, 2023. The meeting will take place at BioCity in Turku, Finland, and will address two main agenda items. Firstly, the Board of Directors proposes to resolve on the election of new members to the Board. Christine Roth, an Executive Vice President for Bayer Pharmaceuticals' Global Oncology Business Unit, and Marie-Louise Fjllskog, Faron Pharmaceuticals' Chief Medical Officer, have been nominated for election. Secondly, the Board proposes to amend the terms and conditions of the Company's Option Plan 2015, extending the subscription period for shares based on options by two years until September 30, 2025. The proposed amendment aims to enhance the usability of the options and incentivize the management and personnel of the Company. The relevant documents and proposals are available on the Company's website, and the minutes of the meeting will be published on October 6, 2023, at the latest. Shareholders who wish to participate in the meeting must register by September 19, 2023, by providing the necessary information to the Company.